Subject
Editions published in Alzheimer's & dementia (New York, N. Y.) 200
Too many entities requested (425). Only 200 are displayed.
-
The effects of information and communication technologies on informal caregivers of persons living with dementia: A systematic review
-
From brain collections to modern brain banks: A historical perspective
-
The lzheimer's disease rapy with uroaid () study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine-A randomized, double-blind, pl
-
A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease
-
Amyloid β perturbs elevated heme flux induced with neuronal development
-
General and domain-specific cognitive reserve, mild cognitive impairment, and dementia risk in older women
-
White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities
-
Patients with Alzheimer's disease who carry the ε4 allele benefit more from physical exercise
-
A model of lipid dysregulation and altered nutrient status in Alzheimer's disease
-
Elevated phospholipase D isoform 1 in Alzheimer's disease patients' hippocampus: Relevance to synaptic dysfunction and memory deficits.
-
Alzheimer's disease Archimedes condition-event simulator: Development and validation.
-
Effect of donepezil on transcranial magnetic stimulation parameters in Alzheimer's disease.
-
Alzheimer's disease drug development pipeline: 2018.
-
Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials.
-
"Text It" program to track falls in patients with Alzheimer's disease and dementia.
-
Efficacy and safety of the compound Chinese medicine SaiLuoTong in vascular dementia: A randomized clinical trial.
-
Galectin-3 and incident cognitive impairment in REGARDS, a cohort of blacks and whites.
-
Discontinuation and nonpublication of interventional clinical trials conducted in patients with mild cognitive impairment and Alzheimer's disease.
-
Established amyloid-β pathology is unaffected by chronic treatment with the selective serotonin reuptake inhibitor paroxetine.
-
A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease.
-
Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease.
-
Neural correlates of episodic memory in the Memento cohort.
-
Virtual reality-based cognitive-motor training for middle-aged adults at high Alzheimer's disease risk: A randomized controlled trial.
-
Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse.
-
Neuroprotective effect of a new photobiomodulation technique against Aβ25-35 peptide-induced toxicity in mice: Novel hypothesis for therapeutic approach of Alzheimer's disease suggested.
-
Wishes and preferences for an online lifestyle program for brain health-A mixed methods study.
-
From information to follow-up: Ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting.
-
Measuring cognition and function in the preclinical stage of Alzheimer's disease.
-
Donepezil may reduce the risk of comorbidities in patients with Alzheimer's disease: A large-scale matched case-control analysis in Japan.
-
Lifestyle and neurodegeneration in midlife as expressed on functional magnetic resonance imaging: A systematic review.
-
Adherence/Retention Alzheimer's Prevention Initiative Colombia Plan
-
Amyloid-associated increases in longitudinal report of subjective cognitive complaints
Subject - wd:Q27726239